45 completed, 8 terminated, 4 recruiting, 2 active not recruiting. 62 Phase 2, 6 Phase 3, 1 Phase 1.
Follow Fluticasone: new trials by email Literature Review of Fluticasone trials Research Report on Fluticasone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE Dupilumab, Fluticasone - Eosinophilic Esophagitis | Phase 2 | Recruiting | University of Colorado, Denver | 72 | 2024-12-23 | 2025-03-14 |
| BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) Belumosudil, Fluticasone, Azithromycin - Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 45 | 2024-05-31 | 2026-06-10 |
| Advair HFA in Healthy and HAPE Predisposed Subjects Advair HFA, Placebo - Altitude Edema | Phase 1 / Phase 2 | Recruiting | University of Colorado, Denver | 60 | 2023-12-12 | 2025-09-22 |
| Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab - Skin Inflammation, Allergic Contact Dermatitis | Phase 2 / Phase 3 | Active not recruiting | Wei-Che Ko | 45 | 2022-11-15 | 2026-06-09 |
| Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray, Placebo Nasal Spray - Eustachian Tube Dysfunction | Phase 2 | Recruiting | Cedars-Sinai Medical Center | 80 | 2022-04-20 | 2026-03-11 |
| FLuticasone in cOvid Treatment (FLOT) Fluticasone Propionate - Covid19 | Phase 2 / Phase 3 | Unknown | University of Medicine and Pharmacy at Ho Chi Minh City | 500 | 2021-09-22 | 2021-09-23 |
| A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis azelastine/fluticasone 137/50 mcg nasal spray, Dymista™ - Allergic Rhinitis | Phase 2 | Completed | Synmosa Biopharma Corp. | 136 | 2020-08-20 | 2023-09-25 |
| Hypertonic Versus Isotonic Saline Irrigations for Chronic Rhinosinusitis Isotonic saline, Hypertonic Nasal Wash, Fluticasone Propionate - Chronic Rhinosinusitis (Diagnosis) | Phase 2 / Phase 3 | Withdrawn | Stanford University | 2020-07-01 | 2021-03-18 | |
| Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis Fluticasone Propionate, Placebo - Blepharitis | Phase 2 | Completed | Nicox Ophthalmics, Inc. | 36 | 2019-03-18 | 2023-06-18 |
| Personalized Treatment Algorithms for Difficult-to-treat Asthma Cholecalciferol, antihistamine, Azithromycin - Asthma in Children | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 21 | 2018-03-16 | 2021-08-20 |
| Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics Anoro Ellipta, Arnuity Ellipta - Chronic Obstructive Pulmonary Disease | Phase 2 | Active not recruiting | University of Virginia | 95 | 2017-11-05 | 2024-11-18 |
| Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma GSK3772847, Placebo, Fluticasone propionate/salmeterol - Asthma | Phase 2 | Completed | GlaxoSmithKline | 165 | 2017-09-14 | 2020-03-02 |
| Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects Fluticasone furoate (FF) Dry Powder Inhaler, Fluticasone propionate (FP) Dry Powder Inhaler, Budesonide (BUD) Turbuhaler - Asthma | Phase 2 | Completed | GlaxoSmithKline | 56 | 2017-02-09 | 2020-07-31 |
| A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils fluticasone propionate/formoterol fumarate breath actuated inhaler, Indacaterol maleate / glycopyrronium bromide capsules - ACOS (Fixed Airflow Obstruction and Elevated Eosinophils) | Phase 2 / Phase 3 | Terminated | Mundipharma Research Limited | 2 | 2016-07-01 | 2016-12-12 |
| Anti-Inflammatory Agent in Sinusitis AZ compound, Collection of Biological Specimens, Intranasal corticosteroid - Nasal Polyps | Phase 2 | Completed | Northwestern University | 43 | 2016-06-20 | 2022-05-25 |
| SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study 1 Food Elimination Diet Therapy, 6 Food Elimination Diet Therapy, 6 Food Elimination Diet (after 1FED failure) - Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis (EoE) | Phase 2 / Phase 3 | Completed | Children's Hospital Medical Center, Cincinnati | 129 | 2016-05-20 | 2020-05-26 |
| Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids 1 Food Elimination Diet, 4 Food Elimination Diet, 4 Food Elimination Diet (post 1FED failure) - Eosinophilic Esophagitis, Eosinophilic Gastrointestinal Disorders (EGIDs) | Phase 2 / Phase 3 | Completed | Children's Hospital Medical Center, Cincinnati | 67 | 2016-03-21 | 2018-08-27 |
| Environmental Control as Add-on Therapy in Childhood Asthma Flovent Diskus, Home Environmental Intervention, Advair Diskus - Asthma | Phase 2 | Completed | Johns Hopkins University | 155 | 2014-10-01 | 2019-11-20 |
| Doxycycline in Treating Patients With Chronic Rhinosinusitis With Nasal Polyps Doxycycline, methylprednisolone, nasal saline spray - Polyp of Nasal Sinus | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 49 | 2014-09-01 | 2018-01-09 |
| Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years. Flutiform 50/5 ug (2 puffs bid) pMDI, Fluticasone 50 ug (2puffs bid) pMDI, Beclometasone Autohaler 50 ug (2 puffs bid) - Mild Persistent Asthma | Phase 2 | Completed | Mundipharma Research Limited | 48 | 2014-02-01 | 2018-10-24 |
Showing 20 of 62. Sign in to see all of them.
Asthma (28) · Pulmonary Disease, Chronic Obstructive (7) · Eosinophilic Esophagitis (6) · Rhinitis, Allergic, Seasonal (4) · Bronchiolitis Obliterans Syndrome (3) · Disease (3) · Rhinitis, Allergic (3) · Bronchiolitis Obliterans (2) · Lung Diseases (2) · Altitude Sickness (1) · Blepharitis (1) · Bronchiectasis (1) · Bronchiolitis (1) · Bronchitis, Chronic (1) · COVID-19 (1)
GlaxoSmithKline (9) · Boehringer Ingelheim (5) · Dey (5) · Children's Hospital Medical Center, Cincinnati (3) · Mundipharma Research Limited (3) · Teva Branded Pharmaceutical Products R&D, Inc. (3) · Novartis Pharmaceuticals (2) · SkyePharma AG (2) · University of Colorado, Denver (2) · Amsterdam UMC, location VUmc (1) · Bausch & Lomb Incorporated (1) · Cedars-Sinai Medical Center (1) · Chiesi Farmaceutici S.p.A. (1) · Dana-Farber Cancer Institute (1) · Icahn School of Medicine at Mount Sinai (1)
United States (42) · Germany (10) · Poland (7) · United Kingdom (7) · Ukraine (6) · South Africa (5) · Bulgaria (4) · Canada (4) · Mexico (4) · Australia (3) · Belgium (3) · Japan (3) · Netherlands (3) · New Zealand (3) · Peru (3)
Imtiaz Chaudry (2) · Marc E Rothenberg, MD, PhD (2) · Anju T Peters, MD (1) · Arthur Wu, MD (1) · Benjamin D Malkin, MD (1) · Corey Cutler, MD, MPH (1) · Corinne Keet, MD PHD (1) · Egbert F Smit, MD PHD (1) · Elizabeth C Matsui, MD MHS (1) · Francesco Blasi, MD (1) · Gurjit K Khurana Hershey, MD, PhD (1)
PMID 20001651, PMID 20299628, PMID 21917440, PMID 23681559, PMID 23682661, PMID 23688323, PMID 23706709, PMID 24525446, PMID 24768678, PMID 25146558, PMID 26251958, PMID 26475726, PMID 27044326, PMID 27622699, PMID 27937064, PMID 29256049, PMID 32484940, PMID 34126278, PMID 35123074, PMID 35524339, PMID 36863390
2009 (1), 2016 (1), 2017 (1), R01DK135692 (1), U54AI117804 (1), U54CA163438 (1)